NCT02830594View on ClinicalTrials.gov

Pembrolizumab and Palliative Radiation Therapy in Treating Patients With Metastatic Esophagus, Stomach, or Gastroesophageal Junction Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

October 5, 2016

Primary Completion Date

January 20, 2022

Study Completion Date

January 16, 2024

Conditions
Gastric AdenocarcinomaGastric Squamous Cell CarcinomaGastroesophageal Junction AdenocarcinomaMetastatic Malignant Neoplasm in the StomachStage IV Esophageal Adenocarcinoma AJCC v7Stage IV Esophageal Squamous Cell Carcinoma AJCC v7
Interventions
RADIATION

External Beam Radiation Therapy

Undergo palliative external beam radiation therapy

OTHER

Laboratory Biomarker Analysis

Correlative studies

BIOLOGICAL

Pembrolizumab

Given IV

Trial Locations (1)

91010

City of Hope Medical Center, Duarte

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER

NCT02830594 - Pembrolizumab and Palliative Radiation Therapy in Treating Patients With Metastatic Esophagus, Stomach, or Gastroesophageal Junction Cancer | Biotech Hunter | Biotech Hunter